



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Avamys

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
PSUSA/9154/202404	Periodic Safety Update EU Single assessment - fluticasone furoate	12/12/2024	14/02/2025	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9154/202404.
IB/0053	B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms	02/10/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



WS/2645/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	06/06/2024	n/a		
II/0051/G	This was an application for a group of variations. Grouped application comprising two type II variations as follows: C.I.11.b – Submission of an updated RMP version 12 in order to remove Headache, Nasal events (including: epistaxis, nasal ulceration, nasal septum perforation and other nasal events), Hypersensitivity, Cataract and glaucoma as Important Identified Risks; to remove Taste and smell disorders, Pyrexia, Systemic corticosteroids effect: adrenal suppression,	16/05/2024	n/a		

	Systemic corticosteroid effect: growth retardation, Psychiatric effects as Important Potential Risks and to remove Use in pregnancy and lactation, Off-label use (sinusitis and children < 6 years of age) as missing information. C.I.11.b – Submission of an updated RMP version 12 in order to remove targeted follow up questionnaires. In addition, the MAH took this opportunity to align the RMP template with GVP Module V Revision 2. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IA/0050	A.7 - Administrative change - Deletion of manufacturing sites	17/07/2023	n/a		
IG/1540	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	01/09/2022	n/a		

IB/0048	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	23/08/2022	n/a		
IB/0047	B.II.e.3.z - Change in test procedure for the immediate packaging of the finished product - Other variation	24/01/2022	n/a		
PSUSA/9154/202104	Periodic Safety Update EU Single assessment - fluticasone furoate	02/12/2021	n/a		PRAC Recommendation - maintenance
N/0045	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/09/2021	14/02/2025	PL	
IAIN/0044/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	17/05/2021	n/a		

IA/0043	A.7 - Administrative change - Deletion of manufacturing sites	10/02/2021	21/04/2021	Annex II and PL	
IAIN/0042	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	15/01/2021	n/a		
IB/0041	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	26/08/2020	21/04/2021	SmPC, Annex II, Labelling and PL	
II/0040	Update of section 4.8 of the SmPC in order to add bronchospasm with a frequency 'not known' and dyspnoea with a frequency 'common' to the list of adverse drug reactions based on post-marketing experience and clinical trials reports. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	02/04/2020	21/04/2021	SmPC and PL	Based on clinical trials and post-marketing data, causal relationship between fluticasone furoate and bronchospasm and/or dyspnoea cannot be excluded. Therefore, bronchospasm and dyspnoea are included in the list of adverse drug reactions in the product information of Avamys.
IB/0039/G	This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-	16/01/2019	n/a		

	sterile medicinal products				
T/0037	Transfer of Marketing Authorisation	12/10/2018	06/12/2018	SmPC, Labelling and PL	
PSUSA/9154/ 201804	Periodic Safety Update EU Single assessment - fluticasone furoate	29/11/2018	n/a		PRAC Recommendation - maintenance
IA/0038/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	23/10/2018	n/a		
WS/1263/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved	16/11/2017	n/a		

	manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size				
IAIN/0034	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	18/08/2017	30/04/2018	SmPC and PL	
IB/0032	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/05/2017	30/04/2018	SmPC, Annex II, Labelling and PL	
IB/0031/G	This was an application for a group of variations. B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation	10/03/2017	n/a		
IB/0029/G	This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.d.1.h - Change in the specification parameters	11/07/2016	n/a		

	and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms				
II/0030/G	This was an application for a group of variations. Type II-Submission of a post authorisation safety study PASS 201077 Retrospective Case-Control Studies of Rare Adverse Events Associated with Intranasal Steroids Type IB-Submission of a new RMP v.11 to include cataracts and glaucoma as identified risks, following the recent PRAC assessment (EMA PSUSA/00009154/201504) In addition, the MAH took the opportunity to reflect in the RMP the current SmPC wording with regard to patient with hepatic impairment agreed in the previously approved variation EMEA/H/C/000770/II/0027. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.13 - Other variations not specifically covered	23/06/2016	n/a		

	elsewhere in this Annex which involve the submission of studies to the competent authority				
II/0027	Update of sections 4.2 and 4.4 of the SmPC to remove warnings associated with hepatic impairment. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the contact details for the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	17/12/2015	07/03/2016	SmPC and PL	The MAH has provided safety data showing that moderate or severe hepatic impairment is not expected to result in a clinically relevant effect when the recommended intranasal fluticasone furoate dose is used. The corresponding wording in sections 4.2 and 4.4 of the SmPC and the Package Leaflet has been deleted accordingly.
N/0028	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/12/2015	07/03/2016	PL	
PSUSA/9154/201504	Periodic Safety Update EU Single assessment - fluticasone furoate	03/12/2015	n/a		PRAC Recommendation - maintenance
II/0026	Update of section 4.8 of the SmPC to add the new ADR nasal septum perforation with a frequency classification of very rare. The Package leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives in Malta, France, Cyprus and the UK in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	22/10/2015	07/03/2016	SmPC and PL	N/A

IA/0024	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	31/07/2015	n/a		
IAIN/0023/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	08/05/2015	n/a		
II/0022	Update of the sections 4.2 and 5.2 of the SmPC with modifications to hepatic impairment dose recommendations for fluticasone furoate nasal spray (FFNS). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/03/2015	07/03/2016	SmPC	
II/0020	Update of sections 4.8, 5.1, and 6.5 of the SmPC in order to incorporate the QRD comments received as part of the renewal assessment procedure (EMA/H/C000770/R/0014). The Package Leaflet is updated accordingly.	21/11/2013	28/04/2014	SmPC, Annex II and PL	Update the sections 4.8 and section 5.1 of Avamys SmPC, as well as the corresponding sections in Annexes II and III of Avamys, in order to incorporate the QRD comments received at the renewal assessment procedure (EMA/H/C000770/R/0014). In addition, MAH made slight correction to section 6.5

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				'Nature and contents of container' to clarify that '14.2ml' does not refer to the volume of Avamys suspension, but to the capacity of the glass container, and to update Czech Republic email address in Annex III of Avamys.
IA/0021	A.7 - Administrative change - Deletion of manufacturing sites	28/10/2013	n/a		
N/0019	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/08/2013	28/04/2014	PL	
IB/0018/G	This was an application for a group of variations. B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	18/06/2013	28/04/2014	SmPC	
IG/0279	A.1 - Administrative change - Change in the name and/or address of the MAH	18/04/2013	28/04/2014	SmPC, Labelling and PL	
IG/0275	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	15/03/2013	n/a		
R/0014	Renewal of the marketing authorisation.	18/10/2012	17/12/2012	SmPC, Annex II, Labelling and PL	
IA/0015	B.II.e.7.b - Change in supplier of packaging	01/08/2012	n/a		

	components or devices (when mentioned in the dossier) - Replacement or addition of a supplier				
II/0012	The variation relates to an update of sections 4.4 (Warnings and Precautions), 4.8 (Undesirable effects) and 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics and section 4 'Possible Side Effects' of the Package Leaflet to include information on 'ocular changes' in the treated population following the CHMP assessment of the results from study FFR110537. C.1.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	21/06/2012	20/07/2012	SmPC and PL	The assessment of the study FFR110537 has shown that once-daily Fluticasone Furoate Nasal Spray 110 mcg induces ocular changes. Information regarding 'ocular changes' in treated population was therefore added to the product information.
II/0011	The variation relates to an update by the MAH of sections 4.4 (Warnings and Precautions), 4.8 (Undesirable Effects) and 5.1 (Pharmacodynamic properties) of the SmPC (Summary of Product Characteristics) and section 4 'Possible Side Effects' of the Package Leaflet (PL) to include information on 'growth retardation' in the paediatric use following the CHMP assessment of the results of study FFR101782. C.1.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	21/06/2012	20/07/2012	SmPC and PL	The assessment of the study FFR101782 have shown a one-year course of FFNS spray 110 mcg QD influences growth in pre-pubescent, paediatric subjects 5-8.5 years of age with periannial allergic rhinitis. Information regarding 'growth retardation' in paediatric use was therefore added to the product information.
IG/0150/G	This was an application for a group of variations.	05/04/2012	n/a		

	C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
II/0010	The variation relates to an update of section 4.8 (Undesirable Effects) of the SmPC (Summary of Product Characteristics) and section 4 'Possible Side Effects' of the Package Leaflet (PL) to include 'headache' following the assessment of the latest PSUR. In addition, minor changes have been made in accordance with the QRD template and for consistency throughout the product information. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	16/02/2012	15/03/2012	SmPC and PL	Following the assessment of the latest PSUR of fluticasone furoate, a number of reports on headache following intranasal fluticasone furoate were received from the MAH's Safety Database. A review of the spontaneously received reports, clinical trial data and literature supported the possibility that these events could be due to fluticasone furoate nasal spray. 'Headache' with a 'common' incidence was therefore added to the fluticasone furoate nasal spray product information.
II/0007/G	This was an application for a group of variations. This was an application for a group of variations. Update of Summary of Product Characteristics, Annex II and Package Leaflet. Update of SmPC section 4.8 to add the adverse drug reactions rhinalgia, nasal discomfort and nasal dryness. Update of SmPC sections 4.4 and 4.8 regarding the long-term use of nasal corticosteroids,	22/09/2011	10/11/2011	SmPC, Annex II and PL	Based on results of review of safety data on nasal disorders from the literature, spontaneous reports and clinical trials, rhinalgia, nasal discomfort and nasal dryness were identified as potential adverse reactions in the frequency group 'uncommon'. Furthermore, the labelling was updated with recommended wording following a review of the long-term safety related to nasal corticosteroids.

	as requested by the CHMP. The Package Leaflet has been updated accordingly. In addition, minor linguistic and typographical amendments have been made in the SmPC and PL, and the SmPC, Annex II and PL was aligned with the latest version of the QRD template. This application concerns grouping of variations of type IB (C.I.3.a) and type II (C.I.4). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH				
IB/0008	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	20/10/2011	n/a		
IG/0034/G	This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance	06/01/2011	n/a	Annex II	

	system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
IB/0006	IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_b_03_Replacement/add. of manufacturing site: Primary packaging site - liquid ph. forms	17/02/2010	n/a	Annex II and PL	
IB/0005	To extent the re-test period for the active substance	29/01/2010	n/a		

	IB_17_a_Change in re-test period of the active substance				
II/0004	Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II has been updated with the new version number. Changes to QPPV Update of DDPS (Pharmacovigilance)	17/12/2009	25/01/2010	Annex II	The DDPS has been updated (version 7.2) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements.
II/0003	Inclusion of 'hypersensitivity' in section 4.8 'Undesirable Effects' of the Summary of Product Characteristics (SPC) and section 4 'Possible Side Effects' of the Package Leaflet (PL) accordingly. In addition, the MAH took the opportunity to make minor changes in sections 5.1 of the SPC and sections 3, 4 and 5 of the PL. Finally, the instructions on the use of Avamys in the PL were added. Update of Summary of Product Characteristics and Package Leaflet	19/11/2009	21/12/2009	SmPC and PL	Reports consistent with hypersensitivity reactions to intranasal fluticasone furoate were received from the MAH's Safety Database. A review of the spontaneously received reports, clinical trial data and literature supported the possibility that these events could be due to fluticasone furoate nasal spray. 'Hypersensitivity' with a 'rare' incidence was therefore added to the fluticasone furoate nasal spray product information.
II/0001	Update the sections 4.2, 4.4 and 4.8 of the Summary of Product Characteristics (SPC) with safety information following the assessment of the first PSUR. Relevant sections of the Package Leaflet (PL) were amended in line with the SPC. The details of the Danish local representative were also amended in the PL. The Annex II was updated following the assessment of the RMP (version 05).	23/04/2009	02/06/2009	SmPC, Annex II and PL	Following the assessment of the 1st PSUR of fluticasone furoate, an increased number of adverse drug reactions related to eye disorders was reported, particularly for cataracts and glaucoma. On this basis, the CHMP recommended an update of the product information and the information was subsequently included in the SPC.

	Update of Summary of Product Characteristics and Package Leaflet				
II/0002	Update of Detailed Description of the Pharmacovigilance System (DDPS). Changes to QPPV Update of DDPS (Pharmacovigilance)	19/02/2009	07/04/2009	Annex II	The DDPS has been updated (version 6.2) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS.